79.06
price down icon0.29%   -0.23
after-market Dopo l'orario di chiusura: 78.88 -0.18 -0.23%
loading
Precedente Chiudi:
$79.29
Aprire:
$79.245
Volume 24 ore:
34.37M
Relative Volume:
2.21
Capitalizzazione di mercato:
$204.27B
Reddito:
$63.92B
Utile/perdita netta:
$17.43B
Rapporto P/E:
11.51
EPS:
6.87
Flusso di cassa netto:
$17.04B
1 W Prestazione:
-3.24%
1M Prestazione:
+1.40%
6M Prestazione:
-19.37%
1 anno Prestazione:
-39.03%
Intervallo 1D:
Value
$78.60
$79.92
Intervallo di 1 settimana:
Value
$77.10
$81.35
Portata 52W:
Value
$73.31
$134.63

Merck Co Inc Stock (MRK) Company Profile

Name
Nome
Merck Co Inc
Name
Telefono
908-740-4000
Name
Indirizzo
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Name
Dipendente
75,000
Name
Cinguettio
@Merck
Name
Prossima data di guadagno
2025-02-04
Name
Ultimi documenti SEC
Name
MRK's Discussions on Twitter

Confronta MRK con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
MRK
Merck Co Inc
79.06 204.27B 63.92B 17.43B 17.04B 6.87
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.73 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
149.79 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
73.77 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.30 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
115.77 234.21B 53.22B 12.86B 14.85B 6.39

Merck Co Inc Stock (MRK) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-14 Downgrade Citigroup Buy → Neutral
2025-04-22 Iniziato Cantor Fitzgerald Neutral
2025-02-18 Downgrade Deutsche Bank Buy → Hold
2025-02-10 Downgrade TD Cowen Buy → Hold
2025-01-08 Downgrade Truist Buy → Hold
2024-12-20 Downgrade BMO Capital Markets Outperform → Market Perform
2024-12-10 Ripresa BofA Securities Buy
2024-12-04 Aggiornamento HSBC Securities Hold → Buy
2024-11-15 Iniziato Wolfe Research Peer Perform
2024-11-11 Downgrade Daiwa Securities Buy → Neutral
2024-10-17 Iniziato Bernstein Mkt Perform
2024-03-11 Downgrade Societe Generale Hold → Sell
2024-01-04 Aggiornamento TD Cowen Market Perform → Outperform
2023-11-09 Iniziato Deutsche Bank Buy
2023-10-27 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-10-20 Aggiornamento UBS Neutral → Buy
2023-07-14 Iniziato HSBC Securities Hold
2023-04-13 Aggiornamento Citigroup Neutral → Buy
2023-03-28 Downgrade Societe Generale Buy → Hold
2023-03-13 Downgrade Wells Fargo Overweight → Equal Weight
2023-03-06 Iniziato Jefferies Buy
2023-02-22 Aggiornamento Wolfe Research Peer Perform → Outperform
2023-01-04 Aggiornamento BofA Securities Neutral → Buy
2022-11-18 Iniziato Credit Suisse Outperform
2022-10-10 Aggiornamento Guggenheim Neutral → Buy
2022-09-14 Aggiornamento Berenberg Hold → Buy
2022-07-06 Aggiornamento Daiwa Securities Neutral → Buy
2022-06-06 Ripresa SVB Leerink Outperform
2022-04-06 Ripresa Morgan Stanley Equal-Weight
2021-12-17 Iniziato Goldman Buy
2021-12-16 Iniziato Daiwa Securities Neutral
2021-12-13 Downgrade UBS Buy → Neutral
2021-12-09 Iniziato Wells Fargo Overweight
2021-12-07 Downgrade Guggenheim Buy → Neutral
2021-11-29 Downgrade Citigroup Buy → Neutral
2021-11-19 Iniziato BMO Capital Markets Market Perform
2021-11-01 Aggiornamento Argus Hold → Buy
2021-09-07 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-07-27 Ripresa Truist Buy
2021-05-20 Downgrade Argus Buy → Hold
2021-04-07 Ripresa RBC Capital Mkts Sector Perform
2020-11-10 Ripresa Bernstein Outperform
2020-09-29 Iniziato Berenberg Hold
2020-08-03 Aggiornamento Goldman Neutral → Buy
2020-06-12 Downgrade Wolfe Research Outperform → Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-01-07 Iniziato RBC Capital Mkts Sector Perform
2019-10-17 Ripresa BofA/Merrill Neutral
2019-08-16 Iniziato SVB Leerink Outperform
2019-07-03 Iniziato Mizuho Buy
2019-05-28 Iniziato Goldman Neutral
2019-05-13 Aggiornamento Atlantic Equities Neutral → Overweight
2018-10-16 Reiterato Citigroup Buy
2018-10-09 Ripresa Guggenheim Buy
2018-04-23 Aggiornamento Goldman Neutral → Buy
2018-04-17 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2018-04-05 Aggiornamento Barclays Equal Weight → Overweight
2018-03-12 Aggiornamento Leerink Partners Mkt Perform → Outperform
2018-02-14 Reiterato Leerink Partners Mkt Perform
2018-02-07 Reiterato Morgan Stanley Equal-Weight
2018-01-16 Aggiornamento SunTrust Hold → Buy
Mostra tutto

Merck Co Inc Borsa (MRK) Ultime notizie

pulisher
Jun 18, 2025

Why the Market Dipped But Merck (MRK) Gained Today - Yahoo

Jun 18, 2025
pulisher
Jun 18, 2025

Merck (MRK) Gains as CDC Agenda Omits Gardasil Dose Changes - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Merck stock up as CDC meeting excludes HPV shots (MRK:NYSE) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

Merck (MRK) Expands Deals with Chinese Pharma Companies - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Kennedy's new US vaccine panel to discuss measles shot for children - marketscreener.com

Jun 18, 2025
pulisher
Jun 18, 2025

Merck Stock Analysis: Is Today’s Massive 2% Spike a Breakout? - Daily Chhattisgarh News

Jun 18, 2025
pulisher
Jun 18, 2025

Merck: Phase 3 trial in prostate cancer - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Merck Doses First Patient in Phase 3 Trial of Prostate Cancer Drug Candidate - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Merck (MRK) Begins Phase 3 Trial for New Prostate Cancer Treatment | MRK Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Breakthrough Prostate Cancer Drug Enters Phase 3 Trial: New Hope for 31% Survival Rate Disease - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

2 Dividend Stocks to Buy and Never Sell - The Motley Fool

Jun 18, 2025
pulisher
Jun 18, 2025

Dividend Growth Remains a Key Priority for Merck - Insider Monkey

Jun 18, 2025
pulisher
Jun 17, 2025

Merck (MRK) Dips More Than Broader Market: What You Should Know - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer - CNBC

Jun 17, 2025
pulisher
Jun 16, 2025

Supreme Court Decision Lets Fosamax Lawsuit Against Merck (MRK) Proceed - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Merck bid to stop Fosamax suit thwarted by Supreme Court - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy? - Nasdaq

Jun 16, 2025
pulisher
Jun 16, 2025

Merck Manuals Launches AI-powered Search Tool, Providing Enhanced Access to Trusted Medical Information and Resources - PR Newswire

Jun 16, 2025
pulisher
Jun 15, 2025

Goldman Sachs Remains a Buy on Merck & Co (MRK), Sets a $99.00 PT - Insider Monkey

Jun 15, 2025
pulisher
Jun 14, 2025

Merck’s SWOT analysis: stock faces keytruda LOE challenge amid pipeline promise - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Merck (MRK) Secures Landmark FDA Approval for Keytruda in Head and Neck Cancer - Daily Chhattisgarh News

Jun 14, 2025
pulisher
Jun 14, 2025

Immuno-Oncology and Precision Medicine Trends Led by Merck & Pfizer Boost Gastric Cancer Market Growth - openPR.com

Jun 14, 2025
pulisher
Jun 14, 2025

SpringWorks Therapeutics’ SWOT analysis: stock outlook amid Merck acquisition - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit - AOL.com

Jun 13, 2025
pulisher
Jun 13, 2025

Merck (MRK) Boosted by Rising MMR Vaccine Demand Amid Measles Outbreaks - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda - Investopedia

Jun 13, 2025
pulisher
Jun 13, 2025

FDA Approves Merck's Keytruda for Head and Neck Cancer - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Merck's Keytruda gains additional indications in head and neck cancer - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Merck: FDA approves Keytruda for head and neck cancer - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

FDA Approves Merck's Anti-PD-1 Therapy - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

Merck Says FDA Approves Keytruda for Head and Neck Cancer With PD-L1 Expression - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

FDA Approves Merck's Keytruda for Specific Head and Neck Cancer | MRK Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 12, 2025

Merck (MRK) Awaits EU Approval for New Pet Medicine - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Merck Animal Health Gets EU Positive Opinion for Numelvi Tablets for Dogs - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Merck Animal Health Receives EU Cvmp Positive Opinion For Numelvi Tablets For Dogs - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Merck (MRK) Awaits EU Approval for Innovative Canine Drug | MRK Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

RFK Jr.’s New Vaccine Panel Includes Two Paid Witnesses Against Merck - Bloomberg.com

Jun 12, 2025
pulisher
Jun 12, 2025

Merck Animal Health gets EU backing for Numelvi tablets (MRK:NYSE) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

Merck’s canine dermatitis drug Numelvi gets positive EU opinion - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Merck (MRK) Animal Health Receives EU CVMP Positive Opinion for NUMELVI Tablets for Dogs - StreetInsider

Jun 12, 2025
pulisher
Jun 12, 2025

Breakthrough: EU Panel Backs Merck's Novel Dog Itch Treatment That Works From Day One - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Kalkine : Is Merck Set for Strong Payouts This Dividend Season Dow Jones Industrial Average - Kalkine Media

Jun 12, 2025
pulisher
Jun 12, 2025

Exclusive-Kennedy’s new vaccine adviser was expert witness against Merck vaccine - The Mighty 790 KFGO

Jun 12, 2025
pulisher
Jun 12, 2025

Controversy Surrounds Merck (MRK) Due to Vaccine Litigation Ties - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

RFK Jr’s vaccine advisor has worked against Merck shot (MRK) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

Exclusive-Kennedy's new vaccine adviser was expert witness against Merck vaccine - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Merck (MRK) Initiates Late-Stage Dengue Vaccine Trial - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Merck: Phase 3 trial for dengue vaccine - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Merck begins late-stage trial for single dose dengue vaccine - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

Merck (MRK) Launches Key Phase 3 Trial for Dengue Vaccine | MRK Stock News - GuruFocus

Jun 12, 2025

Merck Co Inc Azioni (MRK) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Merck Co Inc Azioni (MRK) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Smart Dalton E. III
SVP Fin. - Global Controller
Apr 30 '25
Option Exercise
84.71
464
39,305
8,242
Smart Dalton E. III
SVP Fin. - Global Controller
May 02 '25
Option Exercise
83.26
381
31,722
8,464
Romanelli Joseph
President, Human Health Int?l
May 02 '25
Option Exercise
83.26
2,262
188,334
24,061
Romanelli Joseph
President, Human Health Int?l
Apr 30 '25
Option Exercise
84.71
2,063
174,757
22,816
Larson Betty D
EVP, Chief HR Officer
Apr 30 '25
Option Exercise
84.71
11,350
961,458
11,350
Smart Dalton E. III
SVP Fin. - Global Controller
Apr 25 '25
Option Exercise
58.08
5,000
290,400
12,040
Smart Dalton E. III
SVP Fin. - Global Controller
Apr 25 '25
Sale
82.76
4,262
352,723
7,778
drug_manufacturers_general NVS
$115.77
price down icon 0.16%
$289.33
price down icon 0.10%
drug_manufacturers_general PFE
$23.97
price up icon 0.38%
$108.50
price up icon 0.46%
drug_manufacturers_general SNY
$47.86
price up icon 0.50%
Capitalizzazione:     |  Volume (24 ore):